Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer

References

• CookKMFiggWDAngiogenesis inhibitors: current strategies and future prospectsCA Cancer J Clin201060422224320554717
   PubMed Web of Science ®Google Scholar
• HurwitzHIFehrenbacherLHainsworthJDBevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancerJ Clin Oncol200523153502350815908660
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDíaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• YangQYinCLiaoFBevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancerOnco Targets Ther201582407241326366095
   PubMed Web of Science ®Google Scholar
• BennounaJSastreJArnoldDContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• ElezEArgilésGTaberneroJFirst-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405Curr Treat Options Oncol201516115226374340
   PubMed Web of Science ®Google Scholar
• JubbAMHarrisALBiomarkers to predict the clinical efficacy of bevacizumab in cancerLancet Oncol201011121172118321126687
   PubMed Web of Science ®Google Scholar
• LambrechtsDLenzHJde HaasSCarmelietPSchererSJMarkers of response for the antiangiogenic agent bevacizumabJ Clin Oncol20133191219123023401453
   PubMed Web of Science ®Google Scholar
• CaoYVEGF-targeted cancer therapeutics-paradoxical effects in endocrine organsNat Rev Endocrinol201410953053925048037
   PubMed Web of Science ®Google Scholar
• MaruDVenookAPEllisLMPredictive biomarkers for bevacizumab: are we there yet?Clin Cancer Res201319112824282723549876
   PubMed Web of Science ®Google Scholar
• StackerSAAchenMGThe VEGF signaling pathway in cancer: the road aheadChin J Cancer201332629730223419196
   PubMedGoogle Scholar
• YanLMolecular targeted agents–where we are and where we are goingChin J Cancer201332522523223642906
   PubMedGoogle Scholar
• BellouSPentheroudakisGMurphyCFotsisTAnti-angiogenesis in cancer therapy: Hercules and hydraCancer Lett2013338221922823707856
   PubMed Web of Science ®Google Scholar
• YaoXQianCNZhangZFTwo distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implicationsClin Cancer Res200713116116917200351
   PubMed Web of Science ®Google Scholar
• QianCNHuangDWondergemBTehBTComplexity of tumor vasculature in clear cell renal cell carcinomaCancer200911510 Suppl2282228919402071
   PubMed Web of Science ®Google Scholar
• AdighibeOLeekRDFernandez-MercadoMWhy some tumours trigger neovascularisation and others don’t: the story thus farChin J Cancer2016351826873439
   PubMedGoogle Scholar
• QianCNTanMHYangJPCaoYRevisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formationChin J Cancer2016351026747273
   PubMed Web of Science ®Google Scholar
• SimonaviciusNAshendenMvan WeverwijkAPericytes promote selective vessel regression to regulate vascular patterningBlood201212071516152722740442
   PubMed Web of Science ®Google Scholar
• HallCNReynellCGessleinBCapillary pericytes regulate cerebral blood flow in health and diseaseNature20145087494556024670647
   PubMed Web of Science ®Google Scholar
• YinCJiangCLiaoFInitial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancerOnco Targets Ther201471415142225143746
   PubMed Web of Science ®Google Scholar
• CarmelietPJainRKMolecular mechanisms and clinical applications of angiogenesisNature2011473734729830721593862
   PubMed Web of Science ®Google Scholar
• CarmelietPJainRKMolecular mechanisms and clinical applications of angiogenesisNature2011473734729830721593862
   PubMed Web of Science ®Google Scholar
• NagyJAChangSHShihSCDvorakAMDvorakHFHeterogeneity of the tumor vasculatureSemin Thromb Hemost201036332133120490982
   PubMed Web of Science ®Google Scholar
• ZhaoYYXueCJiangWPredictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumabJ Thorac Oncol201271717522011670
   PubMed Web of Science ®Google Scholar
• SaboEBoltenkoASovaYSteinAKleinhausSResnickMBMicroscopic analysis and significance of vascular architectural complexity in renal cell carcinomaClin Cancer Res20017353353711297244
   PubMed Web of Science ®Google Scholar
• JainRKNormalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapyNat Med20017998798911533692
   PubMed Web of Science ®Google Scholar
• PaivaAELousadoLGuerraDAPPericytes in the Premetastatic NicheCancer Res201878112779278629789421
   PubMed Web of Science ®Google Scholar
• Bei ZhangWHZhangWHBA Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal CancerChemotherapy20130201
   Google Scholar
• CaoYZhangZLZhouMPericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinomaCancer2013119231332422811049
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• HayesDFBevacizumab treatment for solid tumors: boon or bust?JAMA2011305550650821285431
   PubMed Web of Science ®Google Scholar
• SitohyBNagyJADvorakHFAnti-VEGF/VEGFR therapy for cancer: reassessing the targetCancer Res20127281909191422508695
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar
• SongSEwaldAJStallcupWWerbZBergersGPDGFRbeta+ peri-vascular progenitor cells in tumours regulate pericyte differentiation and vascular survivalNat Cell Biol20057987087916113679
   PubMed Web of Science ®Google Scholar
• QianCNHijacking the vasculature in ccRCC–co-option, remodelling and angiogenesisNat Rev Urol201310530030423459032
   PubMed Web of Science ®Google Scholar
• SchrimpfCXinCCampanholleGPericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injuryJ Am Soc Nephrol201223586888322383695
   PubMed Web of Science ®Google Scholar
• FrancoMRoswallPCortezEHanahanDPietrasKPericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expressionBlood2011118102906291721778339
   PubMed Web of Science ®Google Scholar
• WeisshardtPTrarbachTDürigJTumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumabHistochem Cell Biol2012137339140122193946
   PubMed Web of Science ®Google Scholar
• KimESSerurAHuangJPotent VEGF blockade causes regression of coopted vessels in a model of neuroblastomaProc Natl Acad Sci U S A20029917113991140412177446
   PubMed Web of Science ®Google Scholar
• FrentzasSSimoneauEBridgemanVLVessel co-option mediates resistance to anti-angiogenic therapy in liver metastasesNat Med201622111294130227748747
   PubMed Web of Science ®Google Scholar
• StarkKPekayvazKMassbergSRole of pericytes in vascular immunosurveillanceFront Biosci201823767781
   Web of Science ®Google Scholar
• SenaIFGPaivaAEPrazeresPGlioblastoma-activated pericytes support tumor growth via immunosuppressionCancer Med2018741232123929479841
   PubMed Web of Science ®Google Scholar
• MezheyeuskiABradic LindhMGurenTKSurvival-associated heterogeneity of marker-defined perivascular cells in colorectal cancerOncotarget2016727419484195827248825
   PubMedGoogle Scholar
• CookeVGLebleuVSKeskinDPericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathwayCancer Cell2012211668122264789
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar